Skip to main content

Table 2 Adverse Events

From: Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients

 

HSCT 2–5 yr

(n = 26)

HSCT > 5 yr

(n = 15)

Chemotherapy (n = 15)

Healthy

(n = 30)

Any adverse events, n (%)

5 (19.2)

3 (20.0)

2 (13.3)

0 (0)

Local adverse events, n (%)

4 (15.4)

2 (13.3)

1 (6.6)

0 (0)

 Pain or tenderness

3 (11.5)

2 (13.3)

1 (6.6)

0 (0)

 Redness

3 (11.5)

2 (13.3)

1 (6.6)

0 (0)

 Induration or edema

1 (3.8)

2 (13.3)

1 (6.6)

0 (0)

 Itching

3 (11.5)

2 (13.3)

1 (6.6)

0 (0)

Systemic adverse events, n (%)

3 (11.5)

1 (6.6)

1 (6.6)

0 (0)

 Headache

1 (3.8)

1 (6.6)

0 (0)

0 (0)

 Myalgia or arthralgia

3 (11.5)

1 (6.6)

0 (0)

0 (0)

 Fatigue

3 (11.5)

0 (0)

1 (6.6)

0 (0)

 Fever

0 (0)

0 (0)

0 (0)

0 (0)

 Systemic allergic reaction

0 (0)

0 (0)

0 (0)

0 (0)

 Nausea or vomiting

0 (0)

0 (0)

0 (0)

0 (0)

 Diarrhea

0 (0)

0 (0)

0 (0)

0 (0)

  1. HSCT Hematopoietic stem cell transplantation, N Number